Chemotherapy in neoplastic meningitis

Critical Reviews in Oncology/Hematology

Volumn 60, Issue 3, 2006, Pages 194-200

  Pace, Andrea ^a   Fabi, Alessandra ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Leptomeningeal metastasis; Neoplastic meningitis

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BUSULFAN; CYCLOPHOSPHAMIDE DERIVATIVE; CYTARABINE; CYTOKINE; DIAZIQUONE; DNA TOPOISOMERASE INHIBITOR; FLOXURIDINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IRINOTECAN; MAFOSFAMIDE; MEGESTROL ACETATE; METHOTREXATE; MONOCLONAL ANTIBODY I 131; STEROID; TAMOXIFEN; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; TRANSFORMING GROWTH FACTOR ALPHA;

ASEPTIC MENINGITIS; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CEREBROSPINAL FLUID; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG INDUCED HEADACHE; HUMAN; INJECTION SITE PAIN; LEUKOENCEPHALOPATHY; LYMPHOKINE ACTIVATED KILLER CELL; LYMPHOPROLIFERATIVE DISEASE; MEDULLOBLASTOMA; MENINGEAL METASTASIS; MENINGITIS; METASTASIS; NAUSEA; NEOPLASTIC MENINGITIS; NEUROTOXICITY; NONHUMAN; REVIEW; SOLID TUMOR; SUBARACHNOID SPACE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; MENINGITIS; NEOPLASMS;

EID: 33750730967     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.06.013     Document Type: Review

References (57)

1. Chamberlain M.C. Neoplastic meningitis. Semin Neurol 24 4 (2004) 363-374
2. Groves M.D. The pathogenesis of neoplastic meningitis. Curr Oncol Rep 5 1 (2003) 15-23
3. Chamberlain M.C. Neoplastic meningitis. J Clin Oncol 23 15 (2005) 3605-3613
4. Pavlidis N. The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann Oncol 15 Suppl. 4 (2004) 285-291
5. Kim L., and Glantz M.J. Neoplastic meningitis. Curr Treat Options Oncol 2 (6) December (2001) 517-527
6. Chowdhary S., and Chamberlain M.C. Leptomeningeal metastases: current concepts and management guidelines. J Natl Compr Cancer Netw 3 5 (2005) 693-703
7. Balm M., and Hammack J. Leptomeningeal carcinomatosis. Arch Neurol 53 (1996) 626-632
8. Cokgor I., Friedman A.H., and Friedman H.S. Current options for the treatment of neoplastic meningitis. J Neurooncol 60 1 (2002) 79-88
9. Kreuzberg B., Kastner J., and Ferda J. The contribution of MRI to the diagnosis of diffuse meningeal lesions. Neuroradiology 46 (3) March (2004) 198-204
10. Chamberlain M.C., Tsao-Wei D., and Groshen S. Neoplastic meningitis-related encephalopathy. Prognostic significance. Neurology 63 (2004) 2156-2161
11. Boogerd W., and Hart A.A. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67 (1991) 1685-1695
12. Chamberlain M.C., and Junck L. Defining patients at risk for neoplastic meningitis: what parameters can be used to determine who should be treated?. Expert Rev Neurother 4 (Suppl. 4) July (2004) S3-S10
13. Berg S.L., and Chamberlain M.C. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 5 (2003) 29-40
14. Shapiro W.R., Young D.F., and Metha B.M. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injection. New Engl J Med 293 (1975) 161-166
15. Jaeckle K.A., Batchelor T., O'Day S.J., et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 57 3 (2002) 231-239
16. Cole B.F., Glantz M.J., Jaeckle K.A., Chamberlain M.C., and Mackowiak J.I. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 97 12 (2003) 3053-3060
17. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy. J Neurooncol 38 (1998) 151-157
18. Siegal T., and Lossos A. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 44 (1994) 1462-1469
19. Boogerd W., van den Bent M.J., Koehler P.J., et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40 18 (2004) 2726-2733
20. Bokstein F., Lossos A., and Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82 (1998) 1756-1763
21. Glantz M.J., Cole B.F., Recht L., et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol 16 (1998) 1561-1567
22. Ozdogan M., Samur M., Bozcuk H.S., et al. Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol 33 (2003) 229-231
23. Boogerd W., Dorresteijn L.D.A., van der Sande J.J., et al. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 55 (2000) 117-118
24. Atassi G., Hilgard P., and Pohl J. Antineoplastic activity of ASTA Z 7557 (NSC-34582, INN mafosfamide) on transplantable murine tumors. Invest New Drugs 2 (1984) 169-173
25. Bruntsch U., Groos G., Hiller T.A., Wandt H., Tigges F.J., and Gallmeier W.M. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine. Invest New Drugs 3 3 (1985) 293-296
26. Abele R., Aapro M., Haefliger J., et al. Phase I study of cyclohexylamine and lysine salt of mafosfamide. Cancer Chemother Pharm 16 (1986) 182-183
27. Blaney S.M., Balis F.M., Berg S., et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol 23 7 (2005) 1555-1563
28. Zimm S., Collins J., Curt G., et al. Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone. Cancer Res 44 (1984) 1698-1701
29. Berg S.L., Balis F.M., Zimm S., et al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 10 (1992) 143-148
30. Blaney S., Cole D., Balis F., et al. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53 (1993) 725-727
31. Blaney S.M., Heideman R., Berg S., et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21 (2003) 143-147
32. Ostermann S., Csaika C., Buclin T., et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10 (2004) 3728-3736
33. Blancy S.M., Takimoto C., Murr D.J., et al. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT11) and SN-38 in non-human primates. Cancer Chemother Pharmacol 41 (1998) 464-468
34. Patel M., McCully C., Godwin K., and Balis F.M. Plasma and cerebrospinal fluid of intraventricular temozolomide in non human primates. J Neurooncol 61 (2003) 203-207
35. Sampson J.H., Archer G.E., Villavicencio A.T., et al. Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 5 (1999) 1183-1188
36. Friedman H.S., Archer G.E., McLendon R.E., et al. Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats. Cancer Res 54 (1994) 4710-4714
37. Friedman H.S., Colvin O.M., Shapek S.X., et al. Experimental chemotherapy of human medulloblastoma cell lines and trasplantatable xenografts with bifunctional alkylating agents. Cancer Res 48 (1988) 4189-4195
38. Aaron R.H., Elion G.B., Colvin O.M., et al. Busulfan therapy of central nervous system xenografts in athymic mice. Cancer Chemother Pharmacol 35 (1994) 127-131
39. Archer G.E., Sampson J.H., McLendon R.E., et al. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. J Neurooncol 44 (1999) 233-241
40. Nakagawa H., Yamada M., Fukushima M., and Ikenaka M. Intrathecal 5-fluoro-2′-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study. Cancer Chemother Pharmacol 43 3 (1999) 247-256
41. Najagawa H., Miyahara E., Suzujki T., Wada K., Tamura M., and Fujushima Y. Cotinuous intrathecal administratin of 5-fluoro-2′-deoxyuridine for the treatment of neoplastic meningitis. Neurosurgery 57 2 (2005) 266-280
42. Lashford L.S., Davies G.A., Richardson T.B., et al. A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumours. Cancer 61 (1988) 857-868
43. Smith D.B., Moseley R.P., Begent R.H., et al. Quantitative distribution of 131I labelled monoclonal antibodies administered by intraventricular route. Eur J Cancer 26 2 (1990) 126-136
44. 131I-radiolabelled monoclonal antibodies anti tenascin 81C6 and anti-chondroitin proteoglycan sulphate Me1-14F (ab′)2-a prelimiry report. J Neurooncol 24 (1995) 109-122
45. Herrlinger U., Weller M., and Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol 38 (1998) 233-239
46. Moser R.P., Bruner J.M., and Grimm E.A. Biologic therapy for brain tumors. Cancer Bull 43 (1991) 117-126
47. Papadopoulos N.E., Moser R.P., Grimm E., et al. Intrathecal use of recombinant interleukin-2 (rIL-2) in the treatment of leptomeningeal disease (LMD) from metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 14 (1995) A1307
48. Herrlinger U., Kramm C.M., Johnston K.M., et al. Vaccination for experimental gliomas using GM-CSF transduced glioma cells. Cancer Gene Ther 4 (1997) 345-352
49. Fahkrai H., Dorigo O., Shawler D.L., et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93 (1996) 2909-2914
50. Ram Z., Walbridge S., Oshiro E.M., et al. Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res 54 (1994) 2141-2145
51. Vrionis F.D., Wu J., Qi P., Cano W., and Cherington V. Tumor cells expressing the herpes simplex virus thymidine kinase gene in the treatment of Walker 256 meningeal neoplasia in rats. J Neurosurg 84 (1996) 250-257
52. Viola J.J., Ram Z., Walbridge S., et al. Adenovirally mediated gene transfer into experimental solid brain tumors and leptomeningeal cancer cells. J Neurosurg 82 (1995) 70-76
53. Fotios D.V. Gene therapy of neoplastic meningosis. J Neurooncol 38 (1998) 241-244
54. Siegal T. Toxicity of treatment for neoplastic meningitis. Curr Oncol Rep 5 1 (2003) 41-49
55. Grossman S.A., Finkelstein D.M., Ruckdeschel J.C., et al. Randomised prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 11 (1993) 561-569
56. Gilbert M.R. Neoplastic meningitis: a unique disease process or a "Test Tube" for evaluating cancer treatments. Curr Oncol Rep 5 (2003) 11-14
57. Taillibert S., Laigle-Donadey F., Chodkiewicz C., et al. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 75 (2005) 85-99